EP0335900A1 - Muteine des humanen interleukin-4 - Google Patents

Muteine des humanen interleukin-4

Info

Publication number
EP0335900A1
EP0335900A1 EP88900410A EP88900410A EP0335900A1 EP 0335900 A1 EP0335900 A1 EP 0335900A1 EP 88900410 A EP88900410 A EP 88900410A EP 88900410 A EP88900410 A EP 88900410A EP 0335900 A1 EP0335900 A1 EP 0335900A1
Authority
EP
European Patent Office
Prior art keywords
hil
cells
analog
asp
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP88900410A
Other languages
English (en)
French (fr)
Other versions
EP0335900A4 (en
Inventor
Dirk M. Anderson
David J. Cosman
Michael C. Deeley
Kenneth H. Grabstein
Virginia L. Price
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunex Corp
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of EP0335900A1 publication Critical patent/EP0335900A1/de
Publication of EP0335900A4 publication Critical patent/EP0335900A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G10—MUSICAL INSTRUMENTS; ACOUSTICS
    • G10L—SPEECH ANALYSIS TECHNIQUES OR SPEECH SYNTHESIS; SPEECH RECOGNITION; SPEECH OR VOICE PROCESSING TECHNIQUES; SPEECH OR AUDIO CODING OR DECODING
    • G10L15/00—Speech recognition
    • G10L15/06—Creation of reference templates; Training of speech recognition systems, e.g. adaptation to the characteristics of the speaker's voice
    • G10L15/063—Training
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4635—Cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
    • C07K14/395—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts from Saccharomyces
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2304—Interleukin-4 (IL-4)

Definitions

  • the present invention relates generally to lymphokines, and particularly to recombinant interleukin-4 muteins or analog proteins, which induce clonal expansion and maturation of activated B cells and augment generation of cytotoxic T cells.
  • B lymphocytes or B cells, are the precursors of antibody-secreting plasma qells. B cells derive from hematopoietic stem cells located in the bone marrow, via an intermediary cell class known as pre-B cells. B cells are distinguished from pre-B cells by the expression of surface-bound immunoglobulin capable of binding specific antigens. B cells are activated by binding of antigen to membrane receptors, provided that the B cells also interact with specific helper T cells or bind certain soluble growth and differentiation factors.
  • B cell activation is a sequential process involving proliferation and differentiation phases.
  • activated B cell clones multiply to provide an expanded number of cells capable of reacting with the activating antigen.
  • differentiation phase a portion of the activated B cells mature and secrete immunoglobulin as circulating plasma cells.
  • B cell growth factor BCGF
  • BDF B cell differentiation factor
  • Alternative terms for BCGF include “B cell stimulating factor 1” (BSF-1), and “interleukin-4" (IL-4), the latter now being preferred.
  • IL-4 also stimulates growth and differentiation of factor-dependent T cell and myeloid cell classes. Grabstein et al. , supra, reported that murine IL-4 induced proliferation of murine IL-2-dependent and IL-3-dependent T ce ' ll lines. Other studies have indicated that IL-4 stimulates mast cell proliferation and macrophage differentiation.
  • IL-4 The availability of significant quantities of purified IL-4 has facilitated studies of B cell ontogeny and function, and illuminated potential therapeutic uses for this lymphokine.
  • uses presently contemplated for recombinant human IL-4 are treatment of immune deficiency diseases characterized by B cell cytopenias, and induction of B cell differentiation as a treatment for certain B cell related lymphocytic leukemias.
  • IL-4 might also be used to induce and maintain continuous cultures of immunoglobulin-secreting B cells to provide a source of human monoclonal antibodies.
  • IL-4 induces proliferation and differentiation of cytolytic T cells previously exposed to a mitogenic stimulus; this observation indicates that IL-4 can be employed as a therapeutic lymphokine in treatment of viral infection and certain neoplastic conditions.
  • the present invention is directed to recombinant human IL-4 proteins produced using yeast expression systems.
  • Preferred are analog proteins including those having inactivated asparagine-linked
  • This invention also concerns DNA sequences encoding the muteins, recombinant expression vectors comprising the DNA sequences, and processes for making the muteins comprising culturing microorganisms transformed with the recombinant expression vectors.
  • the present invention also provides a method for inducing proliferation of and lytic activity in a population of antitumor cytolytic T lymphocytes (CTL), comprising contacting T cells with a composition comprising a biologically effective quantity of IL-4 in combination with a physiologically acceptable carrier or diluent.
  • CTL antitumor cytolytic T lymphocytes
  • the present invention provides methods for inducing proliferation and activation of antitumor or antiviral cytolytic T lymphocytes in a mammal, e.g., a human, comprising administering a therapeutically effective quantity of a human IL-4 therapeutic composition.
  • FIGURE 1 depicts the nucleotide sequence and corresponding amino acid sequence of wild-type native human IL-4.
  • FIGURE 2 depicts the nucleotide sequence of a DNA sequence
  • FIGURES 3-5 schematically illustrate the construction of a yeast expression vector for production of the hIL-4 mutein D 199
  • FIGURE 6 is a plot showing augmentation of cytolytic T cell generation in primary mixed leukocyte cultures (MLC) by IL-4 and IL-2.
  • FIGURE 7 is a plot illustrating induction of cytolytic activity in long-term MLC by IL-4 and IL-2.
  • a cDNA comprising a nucleotide sequence encoding native human IL-4 was isolated from a cDNA library prepared by reverse transcription of polyadenylated RNA isolated from human peripheral blood T lymphocytes. Synthetic oligonucleotide probes having sequence homology to N-terminal and C-terminal regions of the native human sequence were employed to screen the library by conventional DNA hybridization techniques. Clones from the library comprising plasmid DNAs which hybridized to the probes were isolated and analyzed by restriction endonuclease cleavage, agarose gel electrophoresis, and additional hybridization experiments ("Southern blots") involving the electrophoresed fragments.
  • the hybridizing segment was cleaved to provide a smaller restriction fragment bearing the hIL-4 gene, which was then subcloned and sequenced by conventional techniques.
  • the cDNA encoding mature hIL-4 was then digested with selected restriction endonucleases and reassembled using synthetic oligonucleotides providing predetermined codon changes.
  • the resulting mutant cDNA sequence was inserted into a yeast expression vector under control of a particular promoter. The vector was used to transform an appropriate yeast expression strain, which was grown in culture under conditions promoting derepression of the yeast promoter.
  • the resulting yeast-conditioned culture supernatant provided a protein having hIL-4 biological activity, which was purified as described below.
  • Human interleukin-4" and "hIL-4" refer to a human endogenous secretory protein capable of inducing maturation and proliferation of human B cells, which comprises an amino acid sequence which is substantially homologous to all or a significant part of the sequence set forth in FIGURE 1. Other designations for this molecule include "B-cell stimulating factor” and "B-cell growth factor”.
  • DNA sequence refers to a DNA polymer, in the form of a separate fragment or as a component of a larger DNA construct, which has been derived from DNA isolated at least once in substantially pure form, i.e., in a quantity or concentration enabling identification, manipulation, and recovery of the segment and its component nucleotide sequences by standard biochemical methods, for example, using a cloning vector.
  • Nucleotide sequence refers to a heteropolymer of deoxyribonucleotides.
  • Recombinant expression vector refers to a plasmid comprising a transcriptional unit comprising an assembly of (1) a genetic element or elements having a regulatory role in gene expression, for example, promoters or enhancers, and (2) a structural or coding sequence which is transcribed into mRNA and translated into protein.
  • the transcriptional unit includes a leader sequence enabling extracellular secretion of translated protein by a host cell.
  • Recombinant expression system means a combination of an expression vector and a suitable host microorganism. Yeast expression systems, particularly those employing Saccharomyces cerevisiae, are preferred.
  • “Mutant amino acid sequence” refers to a polypeptide encoded by a nucleotide sequence intentionally made variant from a native sequence.
  • “Mutant protein” or “mutein” means a protein comprising a mutant amino acid sequence.
  • “Substantially homologous,” which can refer both to nucleic acid and amino acid sequences, means that a particular subject sequence, for example, a mutant sequence, varies from a reference sequence by one or more substitutions, deletions, or additions, the net effect of which do not result in an adverse functional dissimilarity between reference and subject sequences. For purposes of the present invention, sequences having greater than 80 percent homology and equivalent biological specific activity are to be considered substantially homologous sequences within the scope of the present invention.
  • Sequences having lesser degrees of homology and comparable bioactivity are to be considered equivalents.
  • “Native sequence” refers to an amino acid or nucleic acid sequence which is identical to a wild-type or native form of a gene or protein.
  • “N-glycosylation site” is defined below.
  • the term “inactivate”, as used in defining the present invention, means to alter a selected N-glycosylation site to eliminate amino acid residues enabling covalent bonding of oligosaccharide moieties.
  • Human IL-4 activity can be observed in cultures of human B cells derived, for example, from suspensions of human tonsillar cells.
  • Enriched B cell populations can be prepared by rosetting T-cells with 2-aminoethylisothiouronium bromide-treated sheep erythrocytes followed by Ficoll-Histopaque (Sigma Chemical Corp., St. Louis, M0,. USA) to eliminate T cells, and Sephadex G10 filtration to remove monocytes, granulocytes, and activated B cells. Following enrichment, B cell preparations can be frozen in liquid 2 prior to use.
  • frozen B cells are thawed, washed, and cultured at 10 cells per well in 100 ⁇ l of RPMI 1640 medium containing 10% fetal calf serum, 5x10 " M 2-merca toethanol, appropriate dilutions of the sample to be tested, and 12.5 ⁇ g/ml of F(ab') 9 fragments goat anti human IgM purified by affinity chromatography. Cultures are incubated for 68-72 hours. During the final 16 hours of the incubation period,
  • the cells receive 0.5 ⁇ Ci [ HJ-thymidine at a specific activity of 75
  • units of activity are calculated by reference to the quantity of hIL-4 which induces 50% of maximal thymidine incorporation. For example, if a 100 ⁇ l sample generates one-half maximal thymidine incorporation at a dilution of 1:20, one unit is defined as the activity contained in 1/20 of 100 ⁇ l, or 5 ⁇ l. The sample would therefore contain 1000 divided by 5, or 200 units per milliliter (U/ml) of hIL-4 activity.
  • nucleotide and Amino Acid Sequences of hIL-4 Proteins The nucleotide and deduced amino acid sequences of a cDNA sequence encoding a wild-type hIL-4 protein are set forth in FIGURE 1.
  • nucleo ides are numbered beginning with the ATG codon corresponding to the N-terminal methionine of the full-length native polypeptide.
  • amino acids are numbered from this methionine residue.
  • the native protein includes a leader sequence of 23 or 25 amino acids preceding a histidine residue providing the N-terminus of the mature secreted protein. On the basis of comparison to the murine
  • FIGURE 2 indicates the nucleotide and encoded amino acid sequence of a synthetic gene encoding a hIL-4 mutein
  • Mutations can be introduced at particular loci by synthesizing oligonucleotides containing a mutant sequence, flanked by restriction sites enabling ligation to fragments of the native sequence. Following ligation, the resulting reconstructed sequence encodes a mutein having the desired amino acid insertion, substitution, or deletion. This approach is illustrated by FIGURES 3-6.
  • oligonucleotide-directed site-specific mutagenesis procedures can be employed to provide an altered gene having particular codons altered according to the substitution, deletion, or insertion required.
  • a strand of the gene to be altered is cloned into an M13 single-stranded phage or other appropriate vector to provide single-stranded DNA comprising either the sense or antisense strand corresponding to the gene to be altered.
  • This DNA is annealed to a fragment of M13 phage to provide a gapped duplex, which is then hybridized to an oligonucleotide primer.
  • the primer is complementary to the sequence surrounding the codon to be altered, but comprises a codon (or an antisense codon complementary to such codon) specifying the new amino acid at the point where substitution is to be effected.
  • the primer will lack the particular codon specifying the amino acid to be deleted, while maintaining the correct reading frame.
  • the primer will include a new codon, at the appropriate location in the sequence, specifying the amino acid to be inserted.
  • the substitute codon, deleted codon, or inserted codon is located at or near the center of the oligonucleotide.
  • oligonucleotide primer employed is determined by the need to optimize stable, unique hybridization at the mutation site with the 5' and 3' extensions being of sufficient length to avoid editing of the mutation by the exonuclease activity of the DNA polymerase employed to fill gaps.
  • oligonucleotides used in accordance with the present invention will usually contain from about 15 to about 25 bases. Oligonucleotides of greater size are not needed.
  • the oligonucleotide primer is then hybridized to the gapped duplex having a single-stranded template segment containing the gene to be altered.
  • the primer is then extended along the template strand by reaction with DNA polymerase I (Klenow fragment), T4 DNA polymerase, or other suitable DNA polymerase.
  • the resulting double stranded DNA is then converted to closed circular DNA by treatment with a DNA ligase, for example, T4 DNA ligase, and the resulting heteroduplex employed to transfeet a suitable host strain, for example E. coli JM105 (Bethesda Research Laboratories, Gaithersburg, MD, USA). Replication of the heteroduplex by the host provides progeny of both strands.
  • the transfected cells are then plated to provide plaques, which are screened using a labelled oligonucleotide corresponding to that used in the mutagenesis procedure. Conditions are employed which result in preferential hybridization of the primer to the mutated DNA but not to the progeny of the parent strand.
  • DNA containing the mutated gene is then isolated and spliced into a suitable expression vector, and the vector employed to transform a host strain. The host strain is then grown in culture to provide the analog protein.
  • purified mixtures of recombinant glycoproteins such as human or murine granulocyte-macrophage colony stimulating factor (GM-CSF) can consist of from 0 to 50% carbohydrate by weight.
  • GM-CSF granulocyte-macrophage colony stimulating factor
  • glycoprotein in recombinant secreted glycoproteins complicates purification procedures, thereby reducing yield.
  • glycoprotein be employed as a therapeutic agent, a possibility exists that recipients will develop allergic reactions to the yeast carbohydrate moieties, requiring therapy to be discontinued. For these reasons, biologically active, homogeneous analogs of immunoregulatory glycoproteins having reduced carbohydrate are desirable for therapeutic use.
  • Functional mutant analogs of human IL-4 having inactivated N-glycosylation sites can be produced by oligonucleotide synthesis and ligation or by site-specific mutagenesis techniques as described above. These analog proteins can be produced in a homogeneous, reduced-carbohydrate form in good yield using yeast expression systems.
  • the present invention concerns analog forms of human IL-4 comprising at least one amino acid substitution, deletion, or insertion inactivating an N-glycosylation site.
  • N-glycosylation sites in eukaryotic proteins are characterized by the amino acid triplet Asn-A -Z, where A is any amino acid, and Z is Ser or Thr.
  • asparagine (Asn) provides a side chain amino group for covalent attachment of carbohydrate.
  • Such a site can be eliminated by substituting another amino acid for Asn or for residue Z, deleting Asn or Z, or inserting a non-Z amino acid between A and Z, or an amino acid other than Asn between Asn and A .
  • substitutions are made conservatively; i.e., the most preferred substitute amino acids are those having physicochemical characteristics resembling those of the residue to be replaced.
  • the potential effect of the deletion or insertion upon biological activity should be considered.
  • an analog hIL-4 according to the present invention is a protein having a mutant amino acid sequence which is substantially homologous to the native sequence of hIL-4, wherein at ' least one occurrence Asn-A -Z in the native sequence has been replaced in the mutant sequence by Asn-A 2-Y or X-A2-A3, where
  • a , and A are the same or different and can be any amino acid
  • X is any amino acid not Asn
  • Y is any amino acid not Z; and Z is Ser or Thr.
  • the native protein contains two putative N-glycosylation sites, the first being the triplet AsnThrThr beginning at residue 62, and the second being AsnGlnSer beginning at residue 129.
  • Appropriately conservative substitute amino acids for Asn include Asp, Gin, Glu, Ala, Gly, Ser, and Thr, of which Asp, Gin, and Glu are preferred.
  • Z is Ser
  • appropriate substitutes are Met, Leu, lie, Val, Asp, Gin, Glu, or Asn; of which Met, Leu, lie, and Val are preferred.
  • conservative substitutions are Val, Glu, Asp, Gin, Gly, or Ala, preferably Val, Glu, Asp or Gin.
  • preferred substitutions to inactivate the hIL-4 N-glycosylation sites are substitution of Val for Thr or Asp for Asn , and Asp for Asn Other conservative amino acid substitutions could be made to provide protein lacking N-glycosylation sites. Muteins bearing such substitution are considered to be equivalents of those specifically disclosed and claimed herein. Ranking substitute amino acids by order of preference for substitution at these positions provides the following Table 1:
  • the present invention also contemplates muteins of hIL-4 in which cysteine residues not essential to biological activity have been deleted or replaced with other amino acids to eliminate sites for intermolecular crosslinking or incorrect intramolecular disulfide bond formation.
  • the native sequence of hIL-4 comprises six cysteine residues, at positions 27, 48, 70, 89, 122, and 151 (see FIG. 1). The first five cysteines have counterparts in the murine homologue, while the last cysteine does not. Thus, the last residue is an appropriate candidate for substitution or deletion.
  • Site specific mutagenesis or oligonucleotide substitution procedures can be employed to delete particular cysteine residues, or provide conservative substitutions.
  • Preferred amino acids for substitution are neutral amino acids such as Gly, Ala, Val, Leu, He, Tyr, Phe, His Trp, Ser, Thr, or Met. Of the foregoing, Ser and Thr are preferred.
  • mutagenesis procedures can also be employed to inactivate KEX2 protease processing sites by deletion, addition, or substitution of residues to alter Arg-Arg, Arg-Lys, or Lys-Arg pairs in a manner eliminating the occurrence of adjacent basic residues. It should be noted that Lys-Lys pairings are considerably less susceptible to KEX2 cleavage, and conversion of Arg-Lys or Lys-Arg to Lys-Lys represents a conservative approach to inactivating KEX2 sites.
  • the resulting muteins are less susceptible to cleavage by the KEX2 protease at locations other than the ⁇ -factor leader sequence where cleavage upon secretion is intended.
  • a Lys-Arg pairing occurs at position 123 of the hIL-4 native sequence. Substitution of a non-Arg amino acid
  • A*5 *X 1 / for Lys or Arg provides a mutant hIL-4 free of internal Arg-Arg
  • a preferred expression system for the IL-4 proteins of this invention employs the yeast ⁇ -factor leader sequence to induce secretion of recombinant protein by a yeast host. Ideally, this system is configured such that the yeast KEX2 protease cleaves the ⁇ -factor leader from the N-terminus of the desired protein upon secretion.
  • An ⁇ -factor leader-hIL-4 protein construction having a Lys-Arg KEX2 protease site immediately adjacent to the N-terminal His residue of wild-type was not always cleaved upon secretion by recombinant yeast.
  • hIL-4 When the tetrapeptide sequence Glu-Ala-Glu-Ala was inserted between the Lys-Arg EX2 recognition site and the N-terminus of hIL-4, more efficient cleavage at the KEX2 site was achieved.
  • the resulting product is an hIL-4 protein having the tetrapeptide Glu-Ala-Glu-Ala at the N-terminus. Potentially, these residues could be removed ii vivo in a yeast strain capable of over-expressing the yeast STE13 gene product, dipeptidyl aminopeptidase A, which cleaves N-terminal Glu-Ala pairs.
  • yeast is preferred for expression of analog and native forms of recombinant human IL-4.
  • An exemplary expression vector is pBCl04 (ATCC 67,232) which contains DNA sequences from pBR322 for selection and replication in E_ ⁇ coli (Ap gene and origin of replication) and yeast DNA sequences including a glucose-repressible alcohol dehydrogenase 2 (ADH2) promoter.
  • ADH2 promoter has been described by Russell et al., J. Biol. Chem.
  • Plasmid pBC104 also comprises the Trpl gene as a selectable marker and the 2 ⁇ origin of replication. Adjacent to the promoter is the ⁇ -factor leader sequence enabling secretion of heterologous proteins from a yeast host. The ⁇ -factor leader sequence is modified to contain, near its 3' end, an
  • pBC104 also comprises a cDNA insert encoding wild-type hIL-4. Details regarding the construction of this plasmid are provided below.
  • yeast vectors which comprise an ⁇ -factor promoter, for example pY ⁇ fHuGM (ATCC 53157), which bears the wild-type human GM-CSF gene. Others are known to those skilled in the art. The construction of pY ⁇ HuGM is described in published European Patent Application EP-A-183,350.
  • yeast strains for transformation will be determined by the nature of the selectable markers and other features of the vector.
  • Appropriate S ⁇ cerevisiae strains for transformation by pBC104 or pY ⁇ HuGM, and various constructions derived from those vectors include strains X2181-1B, available from the Yeast Genetic Stock Center, Berkeley, CA, USA [see below], having the genotype ⁇ trpl gall adel his2; J17 (ATCC 52683; ⁇ his2 adel trpl met14 ura3); and IL166-5B (ATCC 46183; ⁇ hisl trpl).
  • a particularly preferred expression strain, XV2181 is a diploid formed by mating two haploid strains, X2181-1B, available from the Yeast Genetic Stock Center, Department of Biophysics and Medical Physics, University of California, Berkeley, CA 94702, USA; and XV617-1-3B, available from the Department of Genetics, University of Washington, Seattle, WA
  • Trp + transformants in a selective medium consisting of 0.67% yeast nitrogen base, 0.5% casamino acids, 2% glucose, 10 ⁇ g/ml adenine and 20 ⁇ g/ml uracil.
  • Host strains comprising pBC104 or other constructions comprising the ADH2 or ⁇ -factor promoters are grown for expression in a rich medium consisting of 1% yeast extract, 2% peptone, and 1% glucose supplemented with 80 ⁇ g/ml adenine and 80 ⁇ g/ml uracil.
  • Recombinant human IL-4 proteins resulting from fermentation of yeast strains can be purified by single or sequential reversed-phase HPLC steps on a preparative HPLC column, by methods analogous to those described by Urdal et al. , J. Chromatog. 296:171 (1984), and Grabstein et al. , J. Exp. Med. 163:1405 (1986).
  • yeast-conditioned medium containing rhIL-4 can be filtered through a 0.45 ⁇ filter and initially purified by batch adsorption and elution from a cation exchange matrix, for example, S-Sepharose. Pooled fractions from the batch adsorption/elution step can then be pumped, at a flow rate of 100 ml/min, onto a 5 cm x 30 cm column packed with 10-20 ⁇ reversed phase silica (Vydac, The Separations Group, Hesperia, CA, USA).
  • a cation exchange matrix for example, S-Sepharose
  • the column can be equilibrated in 0.1% trifluoroacetic acid in water prior to the application of the yeast-condi ioned medium and then flushed with this solvent following application of the medium to the column until the optical absorbance at 280 nm of the effluent approaches baseline values.
  • a gradient of 0.1% trifluoroacetic acid in acetonitrile can be established that leads from 0 to 60-100% Solvent B at a rate of change of 1-2% per minute and at a flow rate of 100 ml/min.
  • Solvent B At a suitable time (10-20 minutes) following initiation of the gradient, one minute fractions are collected and aliquots of the fractions analyzed for protein content by polyacrylamide gel electrophoresis and fluorescamine protein determination. Additional HPLC or cation-exchange chromatographic steps can be employed if indicated.
  • HIL-4 proteins represent promising therapeutic agents for treatment of immune deficiencies and neoplastic conditions.
  • a hIL-4 protein in the form of a purified composition comprising the protein in combination with a physiologically acceptable carrier or diluent is administered by continuous parenteral infusion, subcutaneous injection, or other suitable means at an dosage rate effective to induce proliferation of B-cells and/or T-cells.
  • Suitable dosages for IL-4 therapy are from 0.1 to 100 ⁇ g/kg body weight per day.
  • the protein can be used in forms of adoptive immunotherapy wherein particular immune cell classes are isolated, expanded in vitro in the presence of a hIL-4 protein, and readministered with additional hIL-4 as means of inducing tumor regression.
  • hIL-4 proteins can be used in conjunction with human interleukin-2.
  • Cytolytic T lymphocytes also known as cytotoxic or effector T cells, are receptor-bearing, antigen-specific lymphocytes. Alloreactive CTL lyse target cells that display major histocompatibility gene complex (MHC) antigens identical to those of the allogeneic cells used to stimulate or induce the cytolytic cells. CTL specific for viral and/or tumor antigens are "restricted” in their recognition of antigens, in that antigen-bearing target cells must also display MHC antigens identical to those of the CTL themselves. CTL control viral replication by killing cells expressing virus-associated membrane antigens, and have also been indirectly implicated in immune surveillance and destruction of certain neoplastic cell types.
  • MHC major histocompatibility gene complex
  • CTL generation is studied most simply in mixed leukocyte cultures (MLC), wherein lymphocytes from genetically dissimilar (allogeneic) individuals are cocultured to induce T cell proliferation.
  • MLC mixed leukocyte cultures
  • T cells are specific for foreign MHC antigens, (present on cells of one individual and not the other) and are referred to as alloreactive T cells.
  • CTL activation and differentiation require participation by CTL precursor cells, T "helper" cells, and accessory cells of monocyte/macrophage lineage.
  • CTL response is initiated upon antigen recognition by particular T cell populations; exposure to appropriate antigen triggers lymphokine receptor expression on CTL precursors and lymphokine secretion by helper T cells.
  • Lymphokine binding by CTL precursors induces proliferation and presumably differentiation of antigen-activated CTL precursors to a cytolytic state.
  • a CTL precursor need not necessarily proliferate in order to attain its cytolytic potential; the ability to kill is apparently a differentiated function.
  • the T cell mediated lytic cycle begins with cell-to-cell contact between a viable effector cell and a target cell bearing the appropriate determinant.
  • a viable effector cell Unlike natural killer (NK) cells, which direct cytolytic activity to a broad spectrum of target cells without an overt requirement for antigen activation, CTL lyse with discriminating specificity.
  • NK natural killer
  • CTL lyse with discriminating specificity.
  • a so-called "lethal hit” is administered, in which membrane permeability of the target is disrupted. This event results in osmotic swelling and the ultimate loss of cytoplasm.
  • the effector cell retains the ability to recognize and lyse additional target cells.
  • IL-4 interleukin-2
  • MLC primary mixed leukocyte culture
  • the two lymphokines differ in that IL-2, but not IL-4, induces a lytic population in cultures of unprimed cells in the absence of an overt antigenic stimulus.
  • the specificity of cytolysis induced by IL-4 may have important therapeutic ramifications; the efficacy of adoptive immunotherapy may be enhanced if side effects attributable to introduction of non-specific lymphokine-activated killer (LAK) cells (e.g., in IL-2 LAK therapy) are reduced.
  • LAK lymphokine-activated killer
  • recombinant IL-4 has been shown to effectively induce proliferation of mitogen-activated T-cells, thymocytes, memory T cells, and alloreactive T-cell clones of different functional subtypes, including CTL.
  • IL-4 has been found to be as effective a stimulus as IL-2 for inducing proliferation of mitogen-activated murine spleen cells bearing the Lyt2+ surface antigen. Thus, it is apparent that IL-4 is an important regulator of T cell growth and function.
  • Example 1 Isolation of cDNA encoding Wild-Type hIL-4 and Expression of Active Protein Using a Yeast Expression System Synthetic oligonucleotides were constructed complimentary to
  • N and C terminal coding region sequences of human IL-4 had the sequence 5'-CAGTTGGGAGGTGAGACCCAT-3' , while the C-terminal probe had the sequence 5'-TCAGCTCGAACACTTTGAATA-3' .
  • the method of synthesis was a standard automated triester method substantially similar to that disclosed by Sood et al. , Nucleic Acids Res. 4:2557 (1977) and Hirose et al., Tet. Lett. 28:2449 (1978). Following synthesis, the oligonucleotide was deblocked and purified by Sephadex G-50 chro atography followed by preparative gel electrophoresis. The oligonucleotides were terminally radiolabelled
  • a cDNA library was constructed by reverse transcription of polyadenylated mRNA isolated from total mRNA extracted from human peripheral blood T lymphocytes (PBT) stimulated with phyt ⁇ riemagglutinin (PHA) and phorbol 12-myristate 13-acetate (PMA).
  • the cDNA was rendered double-stranded using DNA polymerase I and T4 DNA polymerase, methylated with EcoRI methylase to protect EcoRI cleavage sites within the cDNA from subsequent cleavage with EcoRI, ligated to EcoRI linkers, digested with EcoRI to remove all but one copy of the linkers at each end of the cDNA, and ligated to EcoRI-cut and dephosphorylated arms of bacteriophage ⁇ gtlO (Huynh et al., DNA Cloning: A Practical Approach, Glover, ed. , IRL Press pp 49-78).
  • the ligated DNA was packaged into phage particles to generate a library of
  • This DNA segment containing an internal EcoRI cleavage site, was isolated by partial digestion with EcoRI followed by preparative agarose gel electrophoresis, then subcloned into an EcoRI-cut derivative of the standard cloning vector pBR322 (pGembl) containing a polylinker having a unique EcoRI site, a BamHl site and numerous other unique restriction sites.
  • the resulting plasmid was designated pGembl:hIL-4.
  • An exemplary vector substantially similar to pGembl is described by Dente et al. , Nucleic Acids Research 11:1645 (1983).
  • plasmid DNA was purified by standard techniques, then cut with EcoRV and BamHl. The resulting fragment was ligated to Asp718 and BamHl-cut pBC(CSF-l) and the following linker fragment, which provides the KEX2 ⁇ -factor processing site and the initial four amino acids of hIL-4
  • the KEX2 protease cleaves the peptide immediately following the Arg residue. This construct was designated pBC104.
  • pBC103 was prepared by ligating the hIL-4 EcoRV-BamHl fragment, Asp718 and BamHl-cut pBC(CSF-l), and the following oligonucleotide fragment, which encodes an additional His-Gly located immediately following the KEX2 cleavage
  • the resulting expression vectors designated pBC103 and pBC104, were amplified in E. coli and then employed to transform yeast strain XV2181 by the procedures previously referenced.
  • the transformed yeast were grown in nutrient media under conditions promoting derepression of the ADH2 promoter, and the resulting conditioned medium assayed for hIL-4 activity using goat anti-human IgM F(ab) 2 fragments as coactivator.
  • These assays indicated a medium activity of 43,427 U/ml for media conditioned by pBC104-transformed XV2181, and 46,149 U/ml for media conditioned by pBC103-transformed XV2181.
  • a cloning vector comprising the wild-type hIL-4 cDNA sequence shown in FIGURE 1 was digested with the restriction enzymes EcoRV, which cleaves after nucleotide 12 of mature hIL-4, and BamHl, which cleaves downstream from the hIL-4 cDNA in the polylinker region of the vector.
  • the approximate 550 base pair hIL-4 cDNA fragment was subcloned into the pBR322-derived vector pPL-3 by digesting this vector with EcoRV and BamHl (see FIGURE 3). The resulting plasmid was designated L225.
  • a DNA fragment from L225 containing the hIL-4 cDNA was then subcloned into the pBR322-derived vector pGEM-3 (Promega Biotec, Madison, WI, USA) by digesting plasmid L225 with Clal (5' of the hIL-4 cDNA), treating with T4 DNA polymerase to form blunt ends, then digesting with Sstl (3 r to the hIL-4 cDNA in the polylinker region) to remove the cDNA-containing fragment.
  • the vector pGEM-3 was digested with Hindlll, treated with T4 DNA polymerase to form blunt ends, then digested with Sstl.
  • the resulting plasmid was designated L257.
  • This plasmid was used to perform the oligonucleotide replacement mutagenesis described below. All references to numbering of amino acid residues or nucleotides are in accordance with the numbering of FIGURE 1, in which residues and nucleotides are numbered from the N-terminus of the full length translation product, including the putative native signal peptide.
  • the codon encoding asparagine at position 62 was changed to a codon encoding aspartic acid as follows. Plasmid L257 was digested with Hindi, which cuts at nucleotide 152, and Pstl, which cuts at nucleotide 211. The resulting vector fragment was isolated and ligated to the following oligonucleotide A: G ACG GTA ACC GAC ATC TTT GCT GCT AGC AAG GAC...
  • the codon encoding the asparagine residue at position 129 was similarly changed to codon encoding aspartic acid by replacing the DNA fragment from the EcoRI site (nucleotide 360) to the Rsal site
  • the underlined nucleotides represent changes from the wild-type cDNA sequence. Only the A/T to G/C change at position 385 results in an
  • 129 129 codon specifying an amino acid change (Asn to Asp ).
  • the other base changes introduce a Sail restriction site without altering the amino acid sequence.
  • the plasmid derived from plasmid L257 carrying both codon changes was designated pBC132.
  • Example 3 Construction of a Yeast Expression Vector for the hIL-4 Analog GluAlaGluAla-hIL-4-(Asp-62, Asp-129)
  • pIXY120 is substantially identical to pBC104, except for its heterologous insert. As noted below, pBC104 can be used in place of pIXY120 for expression of the muteins of the present invention.
  • the yeast expression vector pIXY120 includes DNA sequences from the following sources:
  • DNA fragments include the TRP-1 gene as a selectable marker in yeast; the yeast 2 micron origin of replication; and the S. cerevisiae ADH2 promoter; and an 85 amino acid signal peptide derived from the gene encoding the secreted peptide ⁇ -factor (See Brake et al., Proc. Natl. Acad. Sci. USA 81:4642 (1984); Kurjan and Herskowitz, Cell 30:933 (1982); and U.S. Patent 4,546,082).
  • An Asp718 restriction site was introduced at nucleotide 237 in the ⁇ -factor signal peptide to facilitate its fusion to heterologous genes.
  • the T residue at nucleotide 241 was changed to a C residue by oligonucleotide-directed in vitro mutagenesis.
  • the presence of the fl origin of replication allows generation of single-stranded copies of the vector when transformed into appropriate (male) strains of E. coli and superinfected with bacteriophage fl. This capability facilitates DNA sequencing of the vector and allows the possibility of doing in vitro mutagenesis.
  • the yeast expression vector pIXY120 was digested with the restriction enzyme Asp718, which cleaves near the 3' end of the ⁇ -factor leader peptide (nucleotide 237), and BamHl, which cleaves in the polylinker.
  • the large vector fragment was purified and ligated to the following two DNA fragments, as depicted in FIGURE 4: 1.
  • the hIL-4 cDNA fragment from the EcoRV site (nucleotide 136 of mature hIL-4) to the BamHl site (3' to the hIL-4 cDNA in the Gembl:hIL-4 polylinker) obtained from plasmid Gembl:hIL-4.
  • the following synthetic oligonucleotide linker 1 which regenerates the 3' end of the ⁇ -factor leader peptide and fuses it in frame to the 5' four amino acids of hIL-4.
  • This oligonucleotide also encodes an eight amino acid identification peptide fused to the N-terminus of hIL-4. This fusion to the hIL-4 protein allowed its detection with specific antibody and was used initially for monitoring the expression and purification of hIL-4.
  • This plasmid designated pIXY118 (FIGURE 5) contains the wild type hIL-4 gene under control of the glucose repressible ADH2 promoter.
  • the ⁇ -factor leader peptide allows secretion of hIL-4 from the yeast cells. Proteolytic processing of the ⁇ -factor leader occurs after the Lys-Arg residues (amino acids 83 and 84) of the ⁇ -factor leader.
  • Plasmid pIXY 118 was digested with EcoRI, which cleaves 5' to the ADH2 promoter, and Sstl, which cleaves 3' to the hIL-4 gene (FIGURE 5).
  • EcoRI EcoRI
  • Sstl Sstl
  • the hIL-4 cDNA insert contained in plasmid pBCl32 from the EcoRV site (from nucleotide 13 of mature hIL-4) to the Sstl site (3' to the hIL-4 cDNA).
  • the resulting plasmid was designated pIXY133. It contained the hIL-4 gene with the Asp 62 and Asp129 codon changes and the eight amino acid fusion peptide at the N-terminus in the yeast expression vector.
  • the final yeast expression plasmid is identical to plasmid pIXY133 except for the oligonucleotide linker sequences used to fuse the hIL-4 cDNA to the ⁇ -factor leader (oligonucleotide 2, FIGURE 6).
  • This yeast expression plasmid was constructed as described below and shown in FIGURE 6:
  • the yeast expression vector pIXY120 was cleaved with the restriction enzymes Asp718 and BamHl as described above.
  • the large vector fragment was ligated together with the following DNA fragments: (1) a hIL-4 (Asp Asp ) cDNA fragment derived from plasmid pIXY133 from EcoRV (at nucleotide 13) to the BamHl site (3' to the hIL-4 cDNA) and (2) a synthetic oligonucleotide (oligonucleotide 2, FIGURE 6) regenerating the 3' end of the ⁇ -factor leader peptide from the Asp718 site (the amino acids Pro-Leu-Asp-Lys-Arg-Glu-Ala-Glu-Ala) and fusing it in-frame to the N-terminal four amino acids of hIL-4 to the EcoRV site.
  • the sequence of this oligonucleotide is set forth below:
  • the resulting plasmid was designated pIXY157 (FIGURE 6).
  • This vector when present in yeast, allows glucose-regulated expression and secretion of a non-glycosyla ed mutant hIL-4.
  • the hIL-4 that is recovered contains the four amino acids Glu-Ala-Glu-Ala at the N-terminus due to lack of processing by the yeast protease dipeptidyl-amino-peptidase A.
  • the large portion of the ⁇ -factor leader is pr teolytically removed after the Lys-Arg residues (amino acids 83 and 84 of the leader) by the product of the KEX2 gene.
  • the foregoing rather lengthy route can be shortcut by excising an EcoRV-BamHI IL-4 cDNA-containing fragment from pBCl04, and digesting the fragment and reassembling it as an EcoRV-Sstl fragment as described above using synthetic oligonucleotides to alter the asparagine-linked glycosylation sites.
  • pBC104 can also be cut with EcoRI and Sstl, and with EcoRI and EcoRV as described above for pIXYll ⁇ , to generate vector EcoRI-Sstl and EcoRI-EcoRV fragments which can be ligated together with the reassembled mutant IL-4 EcoRV-Sstl fragment.
  • This construct can then be cut with Asp718 and BamHl and the resulting vector fragment ligated to (1) an EcoRV-BamHI fragment from the same plasmid comprising the IL-4 analog gene, and (2) the foregoing synthetic oligonucleotide 2, to generate a yeast expression
  • YNB-trp agar plates stored at 4 C. New plates were prepared from frozen glycerol stocks (-70°C) once a week. A preculture was started by inoculating several isolated recombinant yeast colonies into one liter of YNB-trp medium (6.7 g/L Yeast Nitrogen Base, 5 g/L casamino acids, 40 mg/L adenine, 160 mg/L uracil, and 200 mg/L tyrosine), and grown overnight in two 2-liter flasks at 30°C with vigorous shaking. By morning the culture was saturated, in stationary phase, at an 0D600 of 2 to 7.
  • YNB-trp medium 6.7 g/L Yeast Nitrogen Base, 5 g/L casamino acids, 40 mg/L adenine, 160 mg/L uracil, and 200 mg/L tyrosine
  • Two 10 liter fermenters were cleaned and sterilized, then filled to 80% of their working capacity with 12/50 YEP medium (12 g/L yeast extract, 50 g/L peptone) and maintained at 30 C with 500-600 rpm agitation and 10-16 LPM aeration. The inoculum was added. After two hours of growth a nutrient feed of 50% glucose was begun at a rate such that 50 g/L is added over a period of 10-12 hours. The nutrient feed was then shifted to 50% ethanol added to a total of 10 ml/L over 6 hours.
  • 12/50 YEP medium (12 g/L yeast extract, 50 g/L peptone
  • the inoculum was added. After two hours of growth a nutrient feed of 50% glucose was begun at a rate such that 50 g/L is added over a period of 10-12 hours. The nutrient feed was then shifted to 50% ethanol added to a total of 10 ml/L over 6 hours.
  • Total elapsed time of fermentation was approximately 20 hours.
  • the final optical density (600nm) ranged from 30 to 45.
  • the fermenters were cooled to 20°C, and the harvesting procedure begun. First, the pH was adjusted to 8.0 by the addition of 5M NaOH. The fermenter contents were harvested into a clean carboy. The yeast beer was then filtered through a Millipore Pellicon filter system equipped with a 0.45 micron filter cassette, and collected in a sterile 10 L carboy. 62 129
  • the GluAlaGluAla-hIL-4(Asp , Asp ) mutein (IL-4 mutein) in the filtered yeast supernatants was purified by batch absorption on
  • the IL-4 mutein contained in the yeast beer was bound to S-Sepharose gel by batch absorption.
  • 400 ml of S-Sepharose gel slurry (1 volume gel:l volume 0.5M ⁇ -alanine pH 4.0) was added to a volume of 10 L of yeast beer.
  • the pH of this solution was adjusted to pH 3.6 by adding 2N HCl.
  • the solution was then stirred for 10 minutes, and the gel allowed to settle for 30 minutes.
  • the supernatant was decanted through a sintered glass funnel, and the gel slurry containing the recombinant hIL-4 mutein was retained in the funnel.
  • the gel was washed with 500 ml of 50mM ⁇ -alanine pH 4.0, followed by two 1 L washes with 50mM HEPES pH 7.4.
  • the IL-4 mutein is then eluted from the gel by five 200 ml washes with a solution of 0.5M NaCl and 50mM HEPES pH 7.4.
  • the C-4 column was washed with 1 L of a solution of 0.1% TFA/pyrogen free water.
  • the fractions containing recombinant hIL-4 were then applied to the column and eluted with a gradient of 0.1% TFA in acetonitrile at a rate of change of 2% per minute and a flow rate of 100 ml per minute.
  • Peak fractions from C-4 RPC column were pooled and 1/10 volume of 0.5M ⁇ -alanine pH 4 was added. A sample was taken and then - the pool was applied to a 20 ml M0N0-S column (1.6 cm x 10 cm,
  • Example 5 Induction of Cytolytic Activity in .Mixed Leukocyte Culture IL-4 has been shown to stimulate proliferation of certain factor-dependent, non-B lineage cell lines that are normally responsive to IL-2 or to the myeloid growth factor, IL-3. See Grabstein et al., J. Exp. Med. 163:1405 (1986) and Lee et al., Proc. Natl. Acad. Sci. USA 83:2061 (1986). To demonstrate that IL-4 also affects primary T cell populations, particularly with regard to the generation of functionally active T cells, its effects on the generation of CTL in mixed leukocyte cultures (MLC) were assessed.
  • MLC mixed leukocyte cultures
  • Murine IL-4 cDNA was cloned from a library made from sized mRNA of phorbol myristate acetate stimulated EL4 thymoma cells using the cDNA sequence published by Lee et al., Proc. Natl. Acad. Sci. USA 8 ⁇ :2061 (1986). A full length cDNA was subcloned into a yeast expression vector which included pBR322 sequences, the TRP1 gene of yeast for tryptophan selection, the yeast 2 ⁇ origin of replication and the yeast alcohol dehydrogenase 2 (ADH2) promoter and ⁇ -factor leader sequences sufficient to direct synthesis and secretion.
  • yeast expression vector which included pBR322 sequences, the TRP1 gene of yeast for tryptophan selection, the yeast 2 ⁇ origin of replication and the yeast alcohol dehydrogenase 2 (ADH2) promoter and ⁇ -factor leader sequences sufficient to direct synthesis and secretion.
  • the expression plasmid was transformed into yeast strain 79 ( ⁇ , trpl-1, leu2-2) selecting for Trp + transformants. Cultures were grown for purification by inoculating 1 liter of rich medium (1% yeast extract, 2% peptone, -2% glucose) and growing the cultures at.30°C to stationary phase. PMSF and pepstatin A were added at the time of harvest. Cells were removed by centrifugation and filtration through a 0.45 ⁇ m cellulose acetate filter. rIL-4 was purified to homogeneity from yeast supernatant by five cycles of high performance liquid chromatography (HPLC) using solvent systems previously described by Urdal et al., J. Chromatography 296:171 (1984).
  • HPLC high performance liquid chromatography
  • Homogeneous recombinant and natural murine IL-4 exhibit identical specific aaccttiivviittiieess ooff 22..00 xx 1100 U/ ⁇ g, as measured in the B cell proliferation assay described below.
  • MLC incorporating 5 x 10 C57BL/6 murine spleen cells and 5 x 10 gamma irradiated (2,500r) DBA/2 murine splenic stimulating cells were initiated in 16 mm diameter culture wells containing 2 ml culture medium.
  • the culture medium was Dulbecco's Modified Eagle's Medium (DMEM) containing 5% fetal bovine serum (FBS), 5 x 10 M 2-mercaptoethanol and additional amino acids, substantially as disclosed by Cerottini et al. , J. Exp. Med. 140:703 (1974).
  • DMEM Dulbecco's Modified Eagle's Medium
  • FBS fetal bovine serum
  • additional amino acids substantially as disclosed by Cerottini et al. , J. Exp. Med. 140:703 (1974).
  • Cytolytic T lymphocyte generated in MLC supplemented with either IL-4 or IL-2 were alloantigen specific, since lytic activity directed against target cells syngeneic with the responding cell populations was ⁇ 2% of that directed against the specific allogeneic target (data not shown). These data indicate that IL-4 is a potent helper factor for the generation of alloreactive cytolytic T lymphocytes.
  • MLC populations that have been cultured for extended periods of time gradually lose CTL activity but can be re-induced to express high level cytolytic activity by exposure to either allogeneic cells or culture supernatant.
  • IL-4 IL-4 on such MLC memory populations, cells obtained from day 14 C57BL/6 anti-DBA/2 primary MLC were cultured in the presence of recombinant IL-2 or IL-4 and resultant cytolytic activity was measured three days later.
  • lymphokine As shown in FIG. 7 , exposure of the cells to either lymphokine resulted in cellular proliferation and induction of high level cytolytic activity. Lytic activity generated in cultures incubated with IL-4 was approximately 100 fold higher than that observed in control cultures incubated in medium (FIG. 7), and 80-fold higher than the activity of the day 14 population before exposure to exogenous lymphokine (data not shown). CTL activity induced by IL-4 in these cultures, as in primary MLC, was antigen-specific (data not shown). Thus, IL-4, like IL-2, induces expression of antigen-specific cytolytic activity in once-activated, resting memory T cell populations without the need for further antigenic stimulation.
  • Example 7 Dose-Response Comparison of IL-4 and IL-2 To test directly the relative efficiencies of recombinant IL-4 and IL-2 in their capacity to augment CTL generation, multiple concentrations of homogeneous recombinant IL-4 or IL-2 were added to allogeneic primary mixed leukocyte cultures and resultant lytic activity was measured five days later.
  • MLC mixed leukocyte cultures
  • Example 8 Induction of Thymocyte proliferation Thymocytes were obtained from female C57BL/6J mice, 6-10 weeks of age, and cultured at 1.5 x 10 cells/well in 200 ⁇ l volumes of RPMI 1640 containing 5% FBS, culture supplements as described above, and in the presence or absence of 0.25% PHA-M (Gibco).
  • Memory T cells were generated in 14 day primary MLC.
  • Primary MLC were established with 25 x 10 6 C57BL/6 spleen cells and 25 x 10 6
  • Table 4 Response to rIL-4 of Resting and Activated Memory T cells Day 14 Day 3
  • IL-4 proliferation-inducing effects of IL-4 and IL-2.
  • IL-2 is capable of inducing proliferation of cells late in the culture cycle without reactivation by antigen.
  • alloantigen memory cells are significantly more responsive to added IL-4 than added IL-2.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Artificial Intelligence (AREA)
  • Human Computer Interaction (AREA)
  • Virology (AREA)
  • Audiology, Speech & Language Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Computational Linguistics (AREA)
  • Communicable Diseases (AREA)
EP19880900410 1986-12-19 1987-12-04 Human interleukin-4 muteins Withdrawn EP0335900A4 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US94447286A 1986-12-19 1986-12-19
US944472 1986-12-19
US11976387A 1987-11-12 1987-11-12
US119763 1987-11-12

Publications (2)

Publication Number Publication Date
EP0335900A1 true EP0335900A1 (de) 1989-10-11
EP0335900A4 EP0335900A4 (en) 1990-12-27

Family

ID=26817674

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19880900410 Withdrawn EP0335900A4 (en) 1986-12-19 1987-12-04 Human interleukin-4 muteins

Country Status (3)

Country Link
EP (1) EP0335900A4 (de)
AU (1) AU620537B2 (de)
WO (1) WO1988004667A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL80678A (en) * 1985-11-19 1999-05-09 Schering Biotech Corp Human interleukin-4
GB2218420B (en) * 1988-04-12 1992-07-15 British Bio Technology Synthetic gene encoding interleukin 4
EP0378827A1 (de) * 1988-12-21 1990-07-25 Schering Corporation Verwendung von Interleukin-4 für die Senkung des Blutglukosespiegels und/oder für die Gewichtsverminderung
EP0454736A4 (en) * 1989-01-20 1993-05-12 The University Of Melbourne Fibrinolysis
US5494662A (en) * 1992-04-27 1996-02-27 Ono Pharmaceutical Co., Ltd. Stimulator for bone formation
DE4423131A1 (de) * 1994-07-01 1996-01-04 Bayer Ag Neue hIL-4-Mutantenproteine als Antagonisten oder partielle Agonisten des humanen Interleukin 4
US6028176A (en) 1996-07-19 2000-02-22 Bayer Corporation High-affinity interleukin-4 muteins
MY124565A (en) * 1996-07-19 2006-06-30 Bayer Corp High-affinity interleukin-4-muteins

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0230107A1 (de) * 1985-11-19 1987-07-29 Schering Biotech Corporation Säugetier-Interleukin-4

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4518584A (en) * 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
ZA872781B (en) * 1986-05-19 1987-10-05 Immunology Ventures B-cell stimulating factor
AU2257488A (en) * 1987-07-29 1989-03-01 Schering Biotech Corporation Purification of human interleukin-4 expressed in escherichia coli

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0230107A1 (de) * 1985-11-19 1987-07-29 Schering Biotech Corporation Säugetier-Interleukin-4

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO8804667A1 *

Also Published As

Publication number Publication date
AU1055988A (en) 1988-07-15
AU620537B2 (en) 1992-02-20
WO1988004667A1 (en) 1988-06-30
EP0335900A4 (en) 1990-12-27

Similar Documents

Publication Publication Date Title
US5488032A (en) Method of using soluble human interleukin-1 receptors to suppress inflammation
US4965195A (en) Interleukin-7
JP3115318B2 (ja) Ｇｍ―ｃｓｆ及びｉｌ―３を含む融合タンパク質
US5705149A (en) Use of interleukin-7 to stimulate proliferation of hematopoietic cell precursors
EP0243153A2 (de) Menschliche G-CSF-Protein-Expression
FI103987B (fi) Interleukiini-7
US7531644B2 (en) IL-6 receptor•IL-6 direct fusion protein
US5128450A (en) Nonglycosylated human interleukin-3 analog proteins
IE903027A1 (en) Fusion proteins comprising gm-csf and il-3
EP0342206A1 (de) Menschliche interleukin-3 proteine
EP0425536A1 (de) Nichtglycosylierte menschliche interleukin-3-zusammensetzungen
AU620537B2 (en) Human interleukin-4 muteins
US5328988A (en) Interleukin-7
JPH09512165A (ja) インターロイキン１５
EP1094081B1 (de) Fusionsprotein mit direkter verknüpfung des il-6-rezeptors mit il-6
USRE35450E (en) Soluble human interleukin-1 receptors, compositions and method of use
JPH02501827A (ja) ヒト・インターロイキン‐４　ミューテイン
IE920424A1 (en) Method of inhibiting replication of hiv in macrophages
JP3689111B2 (ja) インターロイキン１５
JP4524816B2 (ja) Ｉｌ−６レセプター・ｉｌ−６直結融合蛋白質
AU2901589A (en) Interleukin-1 receptors

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19890522

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

A4 Supplementary search report drawn up and despatched

Effective date: 19901108

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

17Q First examination report despatched

Effective date: 19920708

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19930803